- <![CDATA[ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies]]><![CDATA[Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.]]>onclive · 2mo ago↗ source
- <![CDATA[MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies]]><![CDATA[Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.]]>onclive · 2mo ago↗ source
- <![CDATA[Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question]]><![CDATA[New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.]]>